...
search icon
plx-img

Protalix Biotherapeutics Inc, Common Stock

PLX

ASQ

$1.62

-$0.03

(-1.82%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$132.94M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
33
Volume info-icon
This is the total number of shares traded during the most recent trading day.
867.55K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.05
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.82 L
$3.1 H
$1.62

About Protalix Biotherapeutics Inc, Common Stock

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey. more

Industry: BiotechnologySector: Health Care

Returns

Time FramePLXSectorS&P500
1-Week Return-2.99%-1.91%-1.87%
1-Month Return-45.27%-3.82%8.93%
3-Month Return-31.06%-11.56%-2.39%
6-Month Return-5.26%-10.21%-2.41%
1-Year Return37.29%-9.91%10.88%
3-Year Return47.27%-0.28%46.93%
5-Year Return-50.76%31.29%94.89%
10-Year Return-92.5%75.9%177.5%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue62.90M38.35M47.64M65.49M53.40M[{"date":"2020-12-31","value":96.04,"profit":true},{"date":"2021-12-31","value":58.55,"profit":true},{"date":"2022-12-31","value":72.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":81.53,"profit":true}]
Cost of Revenue10.87M16.35M19.59M22.98M24.32M[{"date":"2020-12-31","value":44.71,"profit":true},{"date":"2021-12-31","value":67.23,"profit":true},{"date":"2022-12-31","value":80.56,"profit":true},{"date":"2023-12-31","value":94.5,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit52.02M22.00M28.05M42.51M29.08M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":42.29,"profit":true},{"date":"2022-12-31","value":53.91,"profit":true},{"date":"2023-12-31","value":81.71,"profit":true},{"date":"2024-12-31","value":55.9,"profit":true}]
Gross Margin82.71%57.37%58.87%64.91%54.46%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":69.36,"profit":true},{"date":"2022-12-31","value":71.18,"profit":true},{"date":"2023-12-31","value":78.48,"profit":true},{"date":"2024-12-31","value":65.84,"profit":true}]
Operating Expenses49.31M42.46M41.06M32.05M25.16M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":86.11,"profit":true},{"date":"2022-12-31","value":83.26,"profit":true},{"date":"2023-12-31","value":64.99,"profit":true},{"date":"2024-12-31","value":51.03,"profit":true}]
Operating Income1.85M(20.46M)(13.01M)10.46M3.92M[{"date":"2020-12-31","value":17.65,"profit":true},{"date":"2021-12-31","value":-195.62,"profit":false},{"date":"2022-12-31","value":-124.42,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":37.45,"profit":true}]
Total Non-Operating Income/Expense(18.47M)(14.24M)(2.77M)(3.79M)474.00K[{"date":"2020-12-31","value":-3895.78,"profit":false},{"date":"2021-12-31","value":-3004.22,"profit":false},{"date":"2022-12-31","value":-583.54,"profit":false},{"date":"2023-12-31","value":-799.16,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(6.52M)(27.58M)(14.40M)8.57M4.15M[{"date":"2020-12-31","value":-76.15,"profit":false},{"date":"2021-12-31","value":-321.99,"profit":false},{"date":"2022-12-31","value":-168.07,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":48.49,"profit":true}]
Income Taxes8.37M6.40M530.00K254.00K1.22M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":76.51,"profit":true},{"date":"2022-12-31","value":6.33,"profit":true},{"date":"2023-12-31","value":3.04,"profit":true},{"date":"2024-12-31","value":14.6,"profit":true}]
Income After Taxes(14.89M)(33.98M)(14.93M)8.31M2.93M[{"date":"2020-12-31","value":-179.16,"profit":false},{"date":"2021-12-31","value":-408.87,"profit":false},{"date":"2022-12-31","value":-179.58,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":35.27,"profit":true}]
Income From Continuous Operations(6.52M)(27.58M)(14.93M)8.31M2.93M[{"date":"2020-12-31","value":-78.48,"profit":false},{"date":"2021-12-31","value":-331.83,"profit":false},{"date":"2022-12-31","value":-179.58,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":35.27,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(14.89M)(33.98M)(14.93M)8.31M2.93M[{"date":"2020-12-31","value":-179.16,"profit":false},{"date":"2021-12-31","value":-408.87,"profit":false},{"date":"2022-12-31","value":-179.58,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":35.27,"profit":true}]
EPS (Diluted)(0.16)(0.63)(0.30)0.050.03[{"date":"2020-12-31","value":-320,"profit":false},{"date":"2021-12-31","value":-1260,"profit":false},{"date":"2022-12-31","value":-600,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":60,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

PLX
Cash Ratio 0.80
Current Ratio 2.49
Quick Ratio 1.69

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PLX
ROA (LTM) 3.53%
ROE (LTM) 10.42%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PLX
Debt Ratio Lower is generally better. Negative is bad. 0.06
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.94

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PLX
Trailing PE 32.40
Forward PE 6.58
P/S (TTM) 2.16
P/B 3.01
Price/FCF NM
EV/R 1.78
EV/Ebitda 14.89
PEG NM

FAQs

What is Protalix Biotherapeutics Inc share price today?

Protalix Biotherapeutics Inc (PLX) share price today is $1.62

Can Indians buy Protalix Biotherapeutics Inc shares?

Yes, Indians can buy shares of Protalix Biotherapeutics Inc (PLX) on Vested. To buy Protalix Biotherapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PLX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Protalix Biotherapeutics Inc be purchased?

Yes, you can purchase fractional shares of Protalix Biotherapeutics Inc (PLX) via the Vested app. You can start investing in Protalix Biotherapeutics Inc (PLX) with a minimum investment of $1.

How to invest in Protalix Biotherapeutics Inc shares from India?

You can invest in shares of Protalix Biotherapeutics Inc (PLX) via Vested in three simple steps:

  • Click on Sign Up or Invest in PLX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Protalix Biotherapeutics Inc shares
What is Protalix Biotherapeutics Inc 52-week high and low stock price?

The 52-week high price of Protalix Biotherapeutics Inc (PLX) is $3.1. The 52-week low price of Protalix Biotherapeutics Inc (PLX) is $0.82.

What is Protalix Biotherapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Protalix Biotherapeutics Inc (PLX) is 33

What is Protalix Biotherapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Protalix Biotherapeutics Inc (PLX) is 3.01

What is the Market Cap of Protalix Biotherapeutics Inc?

The market capitalization of Protalix Biotherapeutics Inc (PLX) is $132.94M

What is Protalix Biotherapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Protalix Biotherapeutics Inc is PLX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top